In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mojave Therapeutics Inc.

Division of Antigenics Inc./Mojave Therapeutics Inc.

Latest From Mojave Therapeutics Inc.

Start-Up Previews (9/02)

A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Cancer Therapeutics, feature Cyclis Pharmaceuticals Inc., Mojave Therapeutics Inc., OncoGeneX Technologies Inc. and Oncologic Inc. Plus these selected Start-Ups across Health Care: CardiacAssist Inc., PharMetrics Inc., Sleep Solutions Inc. and Xoft microTube Inc.

Cancer Therapeutics: Finding a Niche

VCs and CEOs cite the rapid clinical development and recent commercial success of Gleevec and Herceptin as the mere tip of the iceberg of a new generation of gene-based cancer drugs. New treatments are being specifically targeted to genes that up- or down-regulate different characteristics of tumor cells-in particular proliferation, angiogenesis, survival, and apoptosis. We highlight four emerging oncology companies, ranging from firms that have rights to individual compounds against gene targets to those developing broad-based oncology drug delivery platforms.
BioPharmaceutical Business Strategies

Mojave Therapeutics Inc.

To improve antigen recognition, Mojave Therapeutics is harnessing the intracellular antigenic peptide chaperone function of heat shock proteins. It has created a universal cassette for antigen delivery using hsp's, which it calls Javelin technology, that is applicable for active immunotherapy of infectious diseases and cancer.

Can Heat Shock Proteins Improve Immunotherapy?

Therapeutic vaccines derived from antigenic peptides have yet to demonstrate significant efficacy, particularly in cancer. Over the past eight years, a series of observations has led a small group of companies to believe that heat shock proteins possess unique properties that could make them useful adjuvants in vaccines designed to generate specific immune responses against cancers and infectious agents.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Antigenics Inc.
  • Senior Management
  • Timothy Cooke, PhD, CEO
    Brian H Barber, PhD, SVP, CSO
    Christopher Fenimore, VP, Fin.
    Jane M Boswick, VP, Corp. Dev.
  • Contact Info
  • Mojave Therapeutics Inc.
    Phone: (914) 347-0290
    22 Saw Mill River Rd.
    Hawthorne, NY 10532-1533